Amrutanjan Health Care Share Price
Sector: Biotechnology & Drugs
735.35 +7.50 (1.03%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
722.95
Today’s High
743.45
52 Week Low
548.05
52 Week High
861.40
730.00 +0.05 (0.01%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
722.70
Today’s High
742.45
52 Week Low
544.10
52 Week High
862.60
Key Metrics
- Market Cap (In Cr) 2140.7
- Beta 1.01
- Div. Yield (%) 0.63
- P/B 6.46
- TTM P/E 37.07
- Peg Ratio -4.86
- Sector P/E 22.67
- D/E 0
- Open Price 730
- Prev Close 727.85
Amrutanjan Health Care Analysis
Price Analysis
-
1 Week0.49%
-
3 Months15.53%
-
6 Month2.27%
-
YTD1.01%
-
1 Year-3.46%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Amrutanjan Health Care News
SAIL, CIL, Apollo Hospitals, MSTC among 14 stocks to trade ex-dividend today
1 min read . 20 Feb 2024Dividend stocks: Amrutanjan, Premco, P&G shares to trade ex-dividend today
2 min read . 23 Nov 2023Amrutanjan launches campaign with Olympic medalists Mirabai Chanu, Bajrang Punia
1 min read . 02 Dec 2021Amrutanjan Health Care Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 451.82
- Selling/ General/ Admin Expenses Total
- 115.21
- Depreciation/ Amortization
- 6.53
- Other Operating Expenses Total
- 55.2
- Total Operating Expense
- 400.14
- Operating Income
- 51.67
- Net Income Before Taxes
- 69.13
- Net Income
- 50.83
- Diluted Normalized EPS
- 17.58
- Period
- 2025
- Total Assets
- 421.39
- Total Liabilities
- 94.77
- Total Equity
- 326.61
- Tangible Book Valueper Share Common Eq
- 112.38
- Period
- 2025
- Cashfrom Operating Activities
- 50.9
- Cashfrom Investing Activities
- -30.97
- Cashfrom Financing Activities
- -13.49
- Net Changein Cash
- 6.44
- Period
- 2024
- Total Revenue
- 421.23
- Selling/ General/ Admin Expenses Total
- 109.65
- Depreciation/ Amortization
- 6.06
- Other Operating Expenses Total
- 43.22
- Total Operating Expense
- 375.24
- Operating Income
- 45.99
- Net Income Before Taxes
- 61.95
- Net Income
- 44.97
- Diluted Normalized EPS
- 15.65
- Period
- 2024
- Total Assets
- 366.87
- Total Liabilities
- 78.38
- Total Equity
- 288.49
- Tangible Book Valueper Share Common Eq
- 98.96
- Period
- 2024
- Cashfrom Operating Activities
- 27.91
- Cashfrom Investing Activities
- 19.17
- Cashfrom Financing Activities
- -48.27
- Net Changein Cash
- -1.19
- Period
- 2023
- Total Revenue
- 379.64
- Selling/ General/ Admin Expenses Total
- 109.49
- Depreciation/ Amortization
- 5.21
- Other Operating Expenses Total
- 40.51
- Total Operating Expense
- 340.25
- Operating Income
- 39.39
- Net Income Before Taxes
- 53.65
- Net Income
- 39.83
- Diluted Normalized EPS
- 13.62
- Period
- 2023
- Total Assets
- 362.09
- Total Liabilities
- 71.32
- Total Equity
- 290.77
- Tangible Book Valueper Share Common Eq
- 98.63
- Period
- 2023
- Cashfrom Operating Activities
- 20.18
- Cashfrom Investing Activities
- -2.48
- Cashfrom Financing Activities
- -14.99
- Net Changein Cash
- 2.72
- Period
- 2022
- Total Revenue
- 405.84
- Selling/ General/ Admin Expenses Total
- 142.94
- Depreciation/ Amortization
- 3.8
- Other Operating Expenses Total
- 0.3
- Total Operating Expense
- 330.16
- Operating Income
- 75.68
- Net Income Before Taxes
- 90.58
- Net Income
- 67.19
- Diluted Normalized EPS
- 22.98
- Period
- 2022
- Total Assets
- 349.87
- Total Liabilities
- 84.74
- Total Equity
- 265.12
- Tangible Book Valueper Share Common Eq
- 89.91
- Period
- 2022
- Cashfrom Operating Activities
- 52.2
- Cashfrom Investing Activities
- -36.21
- Cashfrom Financing Activities
- -16.7
- Net Changein Cash
- -0.72
- Period
- 2021
- Total Revenue
- 332.84
- Selling/ General/ Admin Expenses Total
- 115.82
- Depreciation/ Amortization
- 3.67
- Other Operating Expenses Total
- 0.33
- Total Operating Expense
- 261.76
- Operating Income
- 71.08
- Net Income Before Taxes
- 81.9
- Net Income
- 61.19
- Diluted Normalized EPS
- 20.91
- Period
- 2021
- Total Assets
- 274.27
- Total Liabilities
- 58.71
- Total Equity
- 215.56
- Tangible Book Valueper Share Common Eq
- 73.23
- Period
- 2021
- Cashfrom Operating Activities
- 89.76
- Cashfrom Investing Activities
- -87.76
- Cashfrom Financing Activities
- -6.32
- Net Changein Cash
- -4.32
- Period
- 2020
- Total Revenue
- 261.48
- Selling/ General/ Admin Expenses Total
- 110.8
- Depreciation/ Amortization
- 4.36
- Other Operating Expenses Total
- 0.87
- Total Operating Expense
- 235.12
- Operating Income
- 26.35
- Net Income Before Taxes
- 34.45
- Net Income
- 25.08
- Diluted Normalized EPS
- 8.58
- Period
- 2020
- Total Assets
- 205.35
- Total Liabilities
- 45.92
- Total Equity
- 159.43
- Tangible Book Valueper Share Common Eq
- 54.36
- Period
- 2020
- Cashfrom Operating Activities
- 18.18
- Cashfrom Investing Activities
- -13.85
- Cashfrom Financing Activities
- -11.69
- Net Changein Cash
- -7.36
- Period
- 2019
- Total Revenue
- 253.23
- Selling/ General/ Admin Expenses Total
- 100.34
- Depreciation/ Amortization
- 3.16
- Other Operating Expenses Total
- 0.6
- Total Operating Expense
- 225.11
- Operating Income
- 28.12
- Net Income Before Taxes
- 35.17
- Net Income
- 24.51
- Diluted Normalized EPS
- 8.61
- Period
- 2019
- Total Assets
- 187.61
- Total Liabilities
- 41.88
- Total Equity
- 145.74
- Tangible Book Valueper Share Common Eq
- 49.71
- Period
- 2019
- Cashfrom Operating Activities
- 21.17
- Cashfrom Investing Activities
- -11.01
- Cashfrom Financing Activities
- -6.95
- Net Changein Cash
- 3.2
- Period
- 2025-03-31
- Total Revenue
- 135.41
- Selling/ General/ Admin Expenses Total
- 31.89
- Depreciation/ Amortization
- 1.62
- Other Operating Expenses Total
- 16.82
- Total Operating Expense
- 119.33
- Operating Income
- 16.08
- Net Income Before Taxes
- 20.86
- Net Income
- 15.18
- Diluted Normalized EPS
- 5.25
- Period
- 2025-03-31
- Total Assets
- 421.39
- Total Liabilities
- 94.77
- Total Equity
- 326.61
- Tangible Book Valueper Share Common Eq
- 112.38
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 50.9
- Cashfrom Investing Activities
- -30.97
- Cashfrom Financing Activities
- -13.49
- Net Changein Cash
- 6.44
- Period
- 2024-12-31
- Total Revenue
- 122.75
- Selling/ General/ Admin Expenses Total
- 31.26
- Depreciation/ Amortization
- 1.66
- Other Operating Expenses Total
- 12.34
- Total Operating Expense
- 101.07
- Operating Income
- 21.68
- Net Income Before Taxes
- 25.99
- Net Income
- 19.25
- Diluted Normalized EPS
- 6.66
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 109.92
- Selling/ General/ Admin Expenses Total
- 29.43
- Depreciation/ Amortization
- 1.65
- Other Operating Expenses Total
- 12.48
- Total Operating Expense
- 97.97
- Operating Income
- 11.95
- Net Income Before Taxes
- 15.94
- Net Income
- 11.8
- Diluted Normalized EPS
- 4.08
- Period
- 2024-09-30
- Total Assets
- 382.59
- Total Liabilities
- 84.81
- Total Equity
- 297.79
- Tangible Book Valueper Share Common Eq
- 102.28
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 16.22
- Cashfrom Investing Activities
- -5.36
- Cashfrom Financing Activities
- -7.5
- Net Changein Cash
- 3.36
- Period
- 2024-06-30
- Total Revenue
- 83.74
- Selling/ General/ Admin Expenses Total
- 22.63
- Depreciation/ Amortization
- 1.59
- Other Operating Expenses Total
- 13.55
- Total Operating Expense
- 81.77
- Operating Income
- 1.96
- Net Income Before Taxes
- 6.35
- Net Income
- 4.62
- Diluted Normalized EPS
- 1.6
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 127.06
- Selling/ General/ Admin Expenses Total
- 27.67
- Depreciation/ Amortization
- 1.53
- Other Operating Expenses Total
- 19.43
- Total Operating Expense
- 112.36
- Operating Income
- 14.7
- Net Income Before Taxes
- 19.6
- Net Income
- 13.66
- Diluted Normalized EPS
- 4.71
- Period
- 2024-03-31
- Total Assets
- 366.87
- Total Liabilities
- 78.38
- Total Equity
- 288.49
- Tangible Book Valueper Share Common Eq
- 98.96
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 27.91
- Cashfrom Investing Activities
- 19.17
- Cashfrom Financing Activities
- -48.27
- Net Changein Cash
- -1.19
- Period
- 2023-12-31
- Total Revenue
- 116.99
- Selling/ General/ Admin Expenses Total
- 25.68
- Depreciation/ Amortization
- 1.58
- Other Operating Expenses Total
- 13.17
- Total Operating Expense
- 97
- Operating Income
- 20
- Net Income Before Taxes
- 23.71
- Net Income
- 17.45
- Diluted Normalized EPS
- 6.04
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Amrutanjan Health Care Technical
Moving Average
SMA
- 5 Day725.8
- 10 Day715.05
- 20 Day716.81
- 50 Day703.33
- 100 Day665.05
- 300 Day704.38
Amrutanjan Health Care Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Novartis India
- 1002.9
- -7.95
- -0.79
- 1248
- 744.95
- 2476.24
- Sms Pharmaceuticals
- 248.55
- 1.8
- 0.73
- 398
- 175
- 2199.77
- Amrutanjan Health Care
- 735.35
- 7.5
- 1.03
- 861.4
- 548.05
- 2140.7
- Vimta Labs
- 438
- -16.25
- -3.58
- 591.5
- 233.25
- 1954.73
- Windlas Biotech
- 891.1
- -2.9
- -0.32
- 1197
- 656.25
- 1863.15
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Novartis India
- 24.99
- 3.21
- 8.34
- 16.56
- Sms Pharmaceuticals
- 29.3
- 3.31
- 9.98
- 8.05
- Amrutanjan Health Care
- 41.65
- 6.48
- 20.26
- 13.26
- Vimta Labs
- 31.61
- 5.49
- 17.42
- 15.73
- Windlas Biotech
- 31.41
- 3.75
- 11.96
- 7.7
Amrutanjan Health Care Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 15-May-25
- Audited Results & Final Dividend
- 12-Feb-25
- Quarterly Results & Interim Dividend
- 12-Nov-24
- Quarterly Results & Interim Dividend
- 13-Aug-24
- Quarterly Results
- 23-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results & Interim Dividend
- 10-Nov-23
- Quarterly Results & Interim Dividend
- 02-Aug-23
- Quarterly Results
- 30-Jun-23
- Buy Back of Shares
- 30-May-23
- Audited Results & Final Dividend
- Meeting Date
- Announced on
- Purpose
- 23-Sept-24
- 19-Aug-24
- AGM
- 29-Dec-23
- 28-Nov-23
- POM
- 21-Sept-23
- 02-Aug-23
- AGM
- -
- 30-Jun-23
- Others
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 15-May-25
- -
- -
- 2.6
- 12-Feb-25
- 18-Feb-25
- 18-Feb-25
- 1
- 05-Nov-24
- 22-Nov-24
- 22-Nov-24
- 1
- 23-May-24
- -
- 13-Sept-24
- 2.6
- 06-Feb-24
- 20-Feb-24
- 20-Feb-24
- 1
- 10-Nov-23
- 23-Nov-23
- 23-Nov-23
- 1
- 30-May-23
- 14-Sept-23
- 14-Sept-23
- 2.6
- 07-Feb-23
- 24-Feb-23
- 24-Feb-23
- 1
- 27-Oct-22
- 15-Nov-22
- 14-Nov-22
- 1
- 24-May-22
- -
- 14-Sept-22
- 2.6


